Watch Live

Tweet TWEET

Actinium to Present at the 24th Annual Wall Street Analyst Forum Institutional Investor Conference

  Actinium to Present at the 24th Annual Wall Street Analyst Forum   Institutional Investor Conference  Management to Communicate Its Future Plans and Meet with Conference Attendees  24th Annual Wall Street Analyst Forum Institutional Investor Conference  Business Wire  NEW YORK -- February 26, 2014  Actinium Pharmaceuticals, Inc. (OTCQB: ATNM.OB) ("Actinium" or "the Company"), a biopharmaceutical Company developing innovative targeted payload immunotherapeutics for the treatment of advanced cancers, announces that Kaushik J. Dave, Ph.D., President and CEO, will present at the 24th Annual Wall Street Analyst Forum Institutional Investor Conference at the University Club of New York, located at 1 West 54th Street, New York, NY, on Monday, March 3, 2014 at 9:05 AM ET.  A live webcast of the presentation will be available at www.visualwebcaster.com/event.asp?id=98054 and via the “Investor Relations” page of the Actinium website, www.actiniumpharmaceuticals.com. A replay of the webcast will be archived on Actinium’s website for 90 days following the presentation.  About Actinium Pharmaceuticals  Actinium Pharmaceuticals, Inc. (ATNM.OB) is a New York-based biopharmaceutical company developing innovative targeted payload immunotherapeutics for the treatment of advanced cancers. Actinium's targeted radiotherapy is based on its proprietary delivery platform for the therapeutic utilization of alpha-emitting actinium-225 and bismuth-213 and certain beta emitting radiopharmaceuticals in conjunction with monoclonal antibodies. The Company’s lead radiopharmaceutical Iomab™-B will be used in preparing patients for hematopoietic stem cell transplant, commonly referred to as bone marrow transplant. The Company is conducting a single, pivotal, multicenter Phase 3 clinical study of Iomab™-B in refractory and relapsed Acute Myeloid Leukemia (AML) patients over the age of 55 with a primary endpoint of durable complete remission. The company’s second program, Actimab-A, is continuing its clinical development in a Phase 1/2 trial for newly diagnosed AML patients over the age of 60 in a single-arm multicenter trial. For more information, please visit www.actiniumpharmaceuticals.com.  For more information:  Visit our web site www.actiniumpharmaceuticals.com  Forward-Looking Statement for Actinium Pharmaceuticals, Inc.  This news release contains “forward-looking statements” as defined in the Private Securities Litigation Reform Act of 1995. These statements are based on management's current expectations and involve risks and uncertainties, which may cause actual results to differ materially from those set forth in the statements. The forward-looking statements may include statements regarding product development, product potential, or financial performance. No forward-looking statement can be guaranteed and actual results may differ materially from those projected. Actinium Pharmaceuticals undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events, or otherwise.  Contact:  Actinium Pharmaceuticals, Inc. Investor/Media Relations: Corey Sohmer, 646-459-4201 csohmer@actiniumpharmaceuticals.com